|Creating the next generation of cancer treatments
March 19, 2013
Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel
Flemington, NJ - March 19, 2013 - Arno Therapeutics, Inc. (OTCBB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that the company has engaged The Ruth Group as its public relations and investor relations agency of record.
By retaining The Ruth Group, Arno strengthens its communications efforts in advance of significant upcoming milestones. Those milestones include the Company's data presentation at the AACR Annual Meeting 2013 in April and the initiation of Phase 1 clinical studies in onapristone, an oral anti-progestin cancer therapy, anticipated in the second half of 2013.
Glenn Mattes, President and CEO of Arno, stated, "The Ruth Group's expertise, established relationships, and strategic counsel in investor relations, and their deep rooted experience in media relations, will help Arno gain visibility with multiple audiences. We are confident that their professionals will assist us in communicating both the progress we are making, as well as the fundamental value of our therapeutic candidates, to both the life sciences investment community and the larger biopharmaceutical industry. We look forward to leveraging The Ruth Group's expertise as we continue to make progress on developing and advancing our unique product candidates."
The Ruth Group (www.theruthgroup.com) will assist Arno by increasing awareness of the Company's corporate focus and growth strategy across the investment community. The Ruth Group will also focus on highlighting the Company's corporate profile among healthcare and biotech industry leaders.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as potential best- or first-in-class products to treat hematologic malignancies and solid tumors. For more information about the company, please visit www.arnothera.com.
About The Ruth Group
The Ruth Group is an investor relations and public relations firm solely focused on life sciences. The firm's professionals offer clients in-depth strategic counsel, and unmatched expertise and knowledge. The Ruth Group's immersion in its clients' challenges and opportunities allows for a unique ability to craft clear communications to meet clients' corporate objectives, and its boutique structure translates to flexibility, creative thinking, and rapid responsiveness. Located in the heart of New York City, and led by founder and CEO Carol Ruth, The Ruth Group shares the fierce passion, energy, innovation, and determination of its clients.
Forward-Looking Statements: This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone, and Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of onapristone or any of our other product candidates, our ability to finance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.The Ruth Group
Stephanie Carrington (investors)
Caitlin Cox (media)
Arno Therapeutics, Inc.